Semaglutide vs Exenatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ozempic, Wegovy
A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Also: Byetta, Bydureon
The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Key Comparison Insights
- Both Semaglutide and Exenatide are FDA approved medications.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Semaglutide | Exenatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1. | Exenatide is a synthetic version of exendin-4 from Gila monster venom. It shares 53% homology with human GLP-1 and resists DPP-4 degradation. Activates GLP-1 receptors to improve glucose control and reduce appetite. |
| Common Dosing | 1-2.4 mg weekly (after titration) Once weekly | 5-10 mcg twice daily or 2 mg weekly Twice daily (IR) or once weekly (ER) |
| Administration | Subcutaneous injection weekly, or oral (Rybelsus) | Subcutaneous injection |
| Typical Duration | Long-term / chronic use | Long-term / chronic use |
| Best Time to Take | Morning, same day each week | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | STEP trials: 15-17% weight loss. FLOW trial: 24% reduction in kidney disease progression (Jan 2025 approval). Wegovy pill: 16.6% weight loss (Dec 2025 approval). Oral Rybelsus approved for CV risk reduction (Oct 2025). | First-in-class GLP-1 agonist with extensive clinical experience since 2005. Studies show 2-4% weight loss and A1C reductions of 0.5-1%. Weekly formulation (Bydureon) provides more consistent levels. |
Frequently Asked Questions: Semaglutide vs Exenatide
What is the difference between Semaglutide and Exenatide?
Semaglutide is a weight loss peptide that a glp-1 receptor agonist with multiple fda approvals including weight loss, t2d, cv risk reduction, and kidney protection. wegovy pill approved dec 2025 as first oral glp-1 for weight loss. Exenatide is a weight loss peptide that the first glp-1 receptor agonist approved for diabetes. derived from gila monster saliva. available in twice-daily and weekly formulations. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide or Exenatide?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide is typically used for weight loss purposes, while Exenatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide and Exenatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide and Exenatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Semaglutide and Exenatide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.